Sofinnova Ventures has provided a $15m extension to the series B round, which is already backed by Novo and Novartis.
US-based cancer-focused biotech company Galera Therapeutics yesterday increased its series B round, backed by pharmaceutical firms Novo and Novartis, to $57m following a $15m extension provided by Sofinnova Ventures.
Galera previously achieved a second close in February 2016 thanks to a $5m extension provided by Enso Ventures.
In October, Novo’s corporate venturing unit Novo Ventures led a $37m first close. Novartis participated in that tranche through its investment arm Novartis Venture Fund, alongside New Enterprise Associates (NEA), Correlation Ventures and…
